These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 33583159)

  • 1. C-X-C chemokine receptor 2 (Cxcr2) promotes hepatocellular carcinoma immune evasion via regulating programmed death-ligand 1 (PD-L1).
    Wan Y; Ge K; Zhou W; Lu J; Jia C; Zhu H
    Biol Chem; 2021 May; 402(6):729-737. PubMed ID: 33583159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
    Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
    Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IL-6 promotes PD-L1 expression in monocytes and macrophages by decreasing protein tyrosine phosphatase receptor type O expression in human hepatocellular carcinoma.
    Zhang W; Liu Y; Yan Z; Yang H; Sun W; Yao Y; Chen Y; Jiang R
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TGF-β1-Induced SOX18 Elevation Promotes Hepatocellular Carcinoma Progression and Metastasis Through Transcriptionally Upregulating PD-L1 and CXCL12.
    Chen J; Feng W; Sun M; Huang W; Wang G; Chen X; Yin Y; Chen X; Zhang B; Nie Y; Fan D; Wu K; Xia L
    Gastroenterology; 2024 Jul; 167(2):264-280. PubMed ID: 38417530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
    Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX
    Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preferential Expression of Programmed Death Ligand 1 Protein in Tumor-Associated Macrophages and Its Potential Role in Immunotherapy for Hepatocellular Carcinoma.
    Park DJ; Sung PS; Lee GW; Cho S; Kim SM; Kang BY; Hur W; Yang H; Lee SK; Lee SH; Jung ES; Seo CH; Ahn J; Choi HJ; You YK; Jang JW; Bae SH; Choi JY; Yoon SK
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KDM1A Promotes Immunosuppression in Hepatocellular Carcinoma by Regulating PD-L1 through Demethylating MEF2D.
    Wang Y; Cao K
    J Immunol Res; 2021; 2021():9965099. PubMed ID: 34307695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of tumor-associated macrophages and PD-L1 in patients with hepatocellular carcinoma and construction of a prognostic model.
    Kong P; Yang H; Tong Q; Dong X; Yi MA; Yan D
    J Cancer Res Clin Oncol; 2023 Sep; 149(12):10685-10700. PubMed ID: 37306737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatocellular Carcinoma Cells Up-regulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-Cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice.
    Chiu DK; Yuen VW; Cheu JW; Wei LL; Ting V; Fehlings M; Sumatoh H; Nardin A; Newell EW; Ng IO; Yau TC; Wong CM; Wong CC
    Gastroenterology; 2020 Aug; 159(2):609-623. PubMed ID: 32275969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy.
    Highfill SL; Cui Y; Giles AJ; Smith JP; Zhang H; Morse E; Kaplan RN; Mackall CL
    Sci Transl Med; 2014 May; 6(237):237ra67. PubMed ID: 24848257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glycolytic activation of peritumoral monocytes fosters immune privilege via the PFKFB3-PD-L1 axis in human hepatocellular carcinoma.
    Chen DP; Ning WR; Jiang ZZ; Peng ZP; Zhu LY; Zhuang SM; Kuang DM; Zheng L; Wu Y
    J Hepatol; 2019 Aug; 71(2):333-343. PubMed ID: 31071366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liver fibrosis promotes immune escape in hepatocellular carcinoma via GOLM1-mediated PD-L1 upregulation.
    Ke MY; Xu T; Fang Y; Ye YP; Li ZJ; Ren FG; Lu SY; Zhang XF; Wu RQ; Lv Y; Dong J
    Cancer Lett; 2021 Aug; 513():14-25. PubMed ID: 33992711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The polymorphism rs975484 in the protein arginine methyltransferase 1 gene modulates expression of immune checkpoint genes in hepatocellular carcinoma.
    Schonfeld M; Zhao J; Komatz A; Weinman SA; Tikhanovich I
    J Biol Chem; 2020 May; 295(20):7126-7137. PubMed ID: 32245889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. M1 Macrophages Induce PD-L1 Expression in Hepatocellular Carcinoma Cells Through IL-1β Signaling.
    Zong Z; Zou J; Mao R; Ma C; Li N; Wang J; Wang X; Zhou H; Zhang L; Shi Y
    Front Immunol; 2019; 10():1643. PubMed ID: 31379842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of liver-targeted drugs on expression of immune-related proteins in hepatocellular carcinoma cells.
    Qiu MJ; He XX; Bi NR; Wang MM; Xiong ZF; Yang SL
    Clin Chim Acta; 2018 Oct; 485():103-105. PubMed ID: 29940148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lenvatinib Targets FGF Receptor 4 to Enhance Antitumor Immune Response of Anti-Programmed Cell Death-1 in HCC.
    Yi C; Chen L; Lin Z; Liu L; Shao W; Zhang R; Lin J; Zhang J; Zhu W; Jia H; Qin L; Lu L; Chen J
    Hepatology; 2021 Nov; 74(5):2544-2560. PubMed ID: 34036623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipopolysaccharide facilitates immune escape of hepatocellular carcinoma cells via m6A modification of lncRNA MIR155HG to upregulate PD-L1 expression.
    Peng L; Pan B; Zhang X; Wang Z; Qiu J; Wang X; Tang N
    Cell Biol Toxicol; 2022 Dec; 38(6):1159-1173. PubMed ID: 35438468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein O-fucosyltransferase 1 promotes PD-L1 stability to drive immune evasion and directs liver cancer to immunotherapy.
    Li Q; Guo W; Qian Y; Li S; Li L; Zhu Z; Wang F; Tong Y; Xia Q; Liu Y
    J Immunother Cancer; 2024 Jun; 12(6):. PubMed ID: 38908854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SIGLEC15, negatively correlated with PD-L1 in HCC, could induce CD8+ T cell apoptosis to promote immune evasion.
    Chen Z; Yu M; Zhang B; Jin L; Yu Q; Liu S; Zhou B; Yan J; Zhang W; Li X; Xu Y; Xiao Y; Zhou J; Fan J; Hung MC; Ye Q; Li H; Guo L
    Oncoimmunology; 2024; 13(1):2376264. PubMed ID: 38988824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blocking Triggering Receptor Expressed on Myeloid Cells-1-Positive Tumor-Associated Macrophages Induced by Hypoxia Reverses Immunosuppression and Anti-Programmed Cell Death Ligand 1 Resistance in Liver Cancer.
    Wu Q; Zhou W; Yin S; Zhou Y; Chen T; Qian J; Su R; Hong L; Lu H; Zhang F; Xie H; Zhou L; Zheng S
    Hepatology; 2019 Jul; 70(1):198-214. PubMed ID: 30810243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.